World-class research. Ultimate impact.
More on impact ›
Advancement of genetic and genomic technologies in recent years has highlighted how a human traits and diseases are underscored by diverse genetic architecture forming a continuum ranging from rare variants of large effect, to common variants with small effect. Genetic Disorders section publishes high-quality research probing the genetic basis of disease, irrespective of whether the disease falls under the traditional labels of Mendelian disorder, complex disease (or related quantitative trait), or oligogenic phenomena that fall somewhere in between. Genetic Disorders encourages multidisciplinary genetic studies that intersect with cell and molecular biology approaches, model organisms, or systems biology applications aimed at elucidating underlying mechanism and therapeutic avenues. Studies exploring variable penetrance, variable expressivity, or gene by environment interaction are also welcome.
- Human genetic studies of a wide range of disorders and related disease-relevant traits. These include, but are not limited to: (1) prenatal and reproductive genetics; (2) Mendelian disorders; (3) complex traits and polygenic disorders; (4) cancer genetics; and (5) epigenetics.
- Genetic and genomic studies describing new causal or contributory loci with priority for research including mechanistic follow-up employing in vitro or in vivo model systems.
- Novel computational approaches applied to the dissection of human genetic disease.
- Translational studies including novel diagnostics, therapeutic target identification, or preclinical studies.
Please see the guidelines about content and novelty below. We welcome manuscripts fulfilling the following criteria:
1. New causal gene explaining a phenotype or disorder in one or more families. Findings should be accompanied by adequate support for causality, especially when the gene discovery is reported in a single family. Support for causality may include population genetics, in silico modeling, or experimental models (in vivo and/or in vitro).
2. New causal variant in a previously established disease gene. Submissions should have adequate phenotype description and support for causality.
3. New mechanistic insights about a known gene or variant. Transcriptomic, proteomic, or novel model organism studies are welcomed.
4. New case report and review of the literature. If it is a previously reported gene/variant, a review of the case in the context of existing cohorts is especially important to compare and contrast what is currently known about the disorder.
5. Mutational analysis of a known gene in a novel disease cohort, and reporting of allelic contribution whether it be novel or known alleles.
6. New diagnostic approach (known or novel gene set). If the approach focuses on a known gene set, a comparison against existing strategies is preferred.
7. New digenic or oligogenic phenomena. If reported in one family, we will prioritize submissions that have adequate genetics and functional support.
1. Study design and power. A study should have adequate sample size to have sufficient power to allow detection of the effect sizes we now expect given current understanding of the genetic architecture of complex traits.
2. Statistical significance. Unless testing a locus with very strong prior evidence (i.e. already robustly associated with a particular trait at stringent significance thresholds, normally p<5x10-8) in a new setting, any claims for novel association should minimally meet Bonferroni multiple testing corrected p-value thresholds. If claiming a completely novel association this would normally be p<5x10-8, findings not meeting this stringent threshold should be carefully placed as "suggestive" or meriting additional follow-up.
3. Studies replicating previously established associations in new population ancestries/ new interesting cohorts are welcome. Replication of a well-established locus in a population of similar ancestry and phenotype would not normally be considered unless there is considerable new biological insight gained from the study. This could take the form of description of a new variant likely to be causal, new mechanistic insight, link with a new phenotype (including molecular phenotypes such as other "omics" data).
4. Studies of well replicated loci but with the addition of new functional data or clinical insights are welcome.
5. Provided the study design is adequate, the study has been well conducted and is scientifically sound, "negative" findings are acceptable. Interpretation of what the "negative" results imply is however necessary, i.e., explain power limitations.
Other examples (as applied to Mendelian or complex traits):
1. New therapeutic approach applied to cells or animals on an established disease model.
2. Known therapeutic approach applied to a new disease model.
Founding Specialty Chief Editor: Jumana Y Al-Aama, King Abdulaziz University, Jeddah, Saudi Arabia.
Indexed in: PubMed, PubMed Central, Scopus, Google Scholar, DOAJ, CrossRef, Chemical Abstracts Service (CAS), EMBASE, AGRICOLA, Semantic Scholar, Ulrich's Periodicals Directory, Science Citation Index Expanded, BIOSIS Citation Index, Biological Abstracts, CLOCKSS, EBSCO, OpenAIRE, Zetoc, Mastermind
PMCID: all published articles receive a PMCID
Genetic Disorders welcomes submissions of the following article types: Brief Research Report, Case Report, Classification, Clinical Trial, Correction, Editorial, General Commentary, Hypothesis and Theory, Methods, Mini Review, Opinion, Original Research, Perspective, Review, Study Protocol, Systematic Review and Technology and Code.
All manuscripts must be submitted directly to the section Genetic Disorders, where they are peer-reviewed by the Associate and Review Editors of the specialty section.
Articles published in the section Genetic Disorders will benefit from the Frontiers impact and tiering system after online publication. Authors of published original research with the highest impact, as judged democratically by the readers, will be invited by the Chief Editor to write a Frontiers Focused Review - a tier-climbing article. This is referred to as "democratic tiering". The author selection is based on article impact analytics of original research published in all Frontiers specialty journals and sections. Focused Reviews are centered on the original discovery, place it into a broader context, and aim to address the wider community across all of Genetics and Pediatrics.
Avenue du Tribunal Fédéral 34
CH – 1005 Lausanne
Tel +41(0)21 510 17 40
Fax +41 (0)21 510 17 01